Quote:
Originally Posted by mamakay 
Sometimes they know what to "suspect", sometimes not.
Deborah mentioned (was it in this thread?) the "insane optimism" with which new vaccines are introduced. Having that zeal is sort of a prerequisite for work in the upper teirs of public health, it seems.
The Immunization program is the child of a "public-private partnership". The "private" end of things, of course, is not going to have a motive to talk about how their product might not actually work out so great. In fact, the people who call the shots there have an obligation to promote their product and make money for their companies, more or less at all costs. So you will never, ever see Wyeth talking about how staph replaces pneumococcus until they have a staph vax, for example.
So we're left relying on the "public" side of things for any hope of an objective evaluation of the possibilities, but in addition to their problem with "insane optimism", those individuals spend quite a lot of time being...very very friendly...with their "private" partners.
I don't think it's corruption, but I do think there's an amazingly powerful groupthink and phenomenal amount of bias that sets in in these circles.
|
Yes, working in any type of public health setting does require a great deal of zeal and 'insane optimism.' Because whatever disease you're working on, you know just how bad it
can be. Measles is not a dread disease for the vast majority of people. But for some, it can be really terrible - disfigurement, brain damage, death. These are the people you're trying to save. And a bias does creep in, but I don't think that it's necessarily all profit-driven. You'd have to be inhuman if you worked in a hospital in San Francisco in the 90s and didn't cheer on AZT, the first antiretroviral, even if the confidence turned out to be a bit misplaced. Because you knew how bad HIV/AIDS was back then.
I'm not saying there shouldn't be any checks on this bias towards optimism, just that it's kind of unavoidable. When you work in public health or biomedical sciences, it is not really all that lucrative and you put in a lot of hours. But you do it because you want to help and of course you're going to be optimistic about new treatments.
Also, I think you'd be surprised how much planning goes into vaccines. I work on Hepatitis C - there's not even a promising vaccine candidate yet. But there are probably about a hundred papers out there talking about what risk groups should be in the clinical trials, how big these trials are going to need to be if the vaccine is genotype-specific, is this vaccine going to need to be subsidized given how it's transmitted (mostly intravenous drug users in industrialized countries), should it be prophylactic or preventative or preventative only among high-risk groups, etc.
And of course profit plays a role. It's unavoidable given how we approach health care. From a utilitarian standpoint, the best thing that pharmaceutical companies could do is drop everything and start to work on malaria treatments and antibiotics that are more effective for tropical diseases. A soul-crushingly low amount of money is spent on this. But given that vaccines actually make relatively little money for pharma companies, I would be more worried about how much drugs like Ambien and Singulair are being pushed.